These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 21105279)
1. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. Lenze EJ; Goate AM; Nowotny P; Dixon D; Shi P; Bies RR; Lotrich FK; Rollman BL; Shear MK; Thompson PA; Andreescu C; Pollock BG J Clin Psychopharmacol; 2010 Dec; 30(6):672-7. PubMed ID: 21105279 [TBL] [Abstract][Full Text] [Related]
2. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. Garfield LD; Dixon D; Nowotny P; Lotrich FE; Pollock BG; Kristjansson SD; Doré PM; Lenze EJ Am J Geriatr Psychiatry; 2014 Oct; 22(10):971-9. PubMed ID: 24021217 [TBL] [Abstract][Full Text] [Related]
3. Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. Lenze EJ; Mantella RC; Shi P; Goate AM; Nowotny P; Butters MA; Andreescu C; Thompson PA; Rollman BL Am J Geriatr Psychiatry; 2011 May; 19(5):482-90. PubMed ID: 20808146 [TBL] [Abstract][Full Text] [Related]
4. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. Lenze EJ; Rollman BL; Shear MK; Dew MA; Pollock BG; Ciliberti C; Costantino M; Snyder S; Shi P; Spitznagel E; Andreescu C; Butters MA; Reynolds CF JAMA; 2009 Jan; 301(3):295-303. PubMed ID: 19155456 [TBL] [Abstract][Full Text] [Related]
5. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. Pelissolo A Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243 [TBL] [Abstract][Full Text] [Related]
6. Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation. Damsbo AG; Kraglund KL; Buttenschøn HN; Johnsen SP; Andersen G; Mortensen JK Cerebrovasc Dis; 2019; 47(1-2):72-79. PubMed ID: 30844812 [TBL] [Abstract][Full Text] [Related]
7. Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population. Mandal T; Bairy LK; Sharma PSVN Eur J Clin Pharmacol; 2020 Jun; 76(6):807-814. PubMed ID: 32253447 [TBL] [Abstract][Full Text] [Related]
10. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Lohoff FW; Narasimhan S; Rickels K Pharmacogenomics J; 2013 Oct; 13(5):464-9. PubMed ID: 22907732 [TBL] [Abstract][Full Text] [Related]
11. Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. Lee EJ; Oh MS; Kim JS; Chang DI; Park JH; Cha JK; Heo JH; Sohn SI; Kim DE; Kim HY; Kim J; Seo WK; Lee J; Park SW; Kim YJ; Lee BC; J Neurol Neurosurg Psychiatry; 2018 Mar; 89(3):271-276. PubMed ID: 29030421 [TBL] [Abstract][Full Text] [Related]
13. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Won ES; Chang HS; Lee HY; Ham BJ; Lee MS Neuropsychobiology; 2012; 66(4):221-9. PubMed ID: 23095326 [TBL] [Abstract][Full Text] [Related]
14. Escitalopram : a review of its use in the management of major depressive and anxiety disorders. Waugh J; Goa KL CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392 [TBL] [Abstract][Full Text] [Related]
15. Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. Rotberg B; Kronenberg S; Carmel M; Frisch A; Brent D; Zalsman G; Apter A; Weizman A J Child Adolesc Psychopharmacol; 2013 Mar; 23(2):117-22. PubMed ID: 23510446 [TBL] [Abstract][Full Text] [Related]
16. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Stein DJ; Andersen HF; Goodman WK Ann Clin Psychiatry; 2005; 17(2):71-5. PubMed ID: 16075659 [TBL] [Abstract][Full Text] [Related]
17. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism. Najjar F; Owley T; Mosconi MW; Jacob S; Hur K; Guter SJ; Sweeney JA; Gibbons RD; Cook EH; Bishop JR J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):467-74. PubMed ID: 26262902 [TBL] [Abstract][Full Text] [Related]
19. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812 [TBL] [Abstract][Full Text] [Related]
20. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Davidson JR; Bose A; Korotzer A; Zheng H Depress Anxiety; 2004; 19(4):234-40. PubMed ID: 15274172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]